GlassScriptPhysician profile
Larisa Litvinova
NPI 1558443739
$661.61
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $236.72 | 2019-2020 | |
| Gilead Sciences, INC. | $198.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $66.00 | 2019-2020 | |
| Amarin Pharma, INC. | $36.54 | 2019 | |
| Allergan, INC. | $34.90 | 2020 | |
| Genentech USA, INC. | $22.47 | 2019 | |
| Sanofi Pasteur INC. | $18.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.52 | 2019 | |
| Merck Sharp & Dohme LLC | $17.33 | 2019 | |
| Lilly USA, LLC | $13.10 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Litvinova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.